CA2447400A1 - Cellules souches caracteristiques de tumeurs cerebrales - Google Patents

Cellules souches caracteristiques de tumeurs cerebrales Download PDF

Info

Publication number: CA2447400A1
Authority: CA; Canada
Prior art keywords: cells; stem cells; brain tumor; tumor; cell
Prior art date: 2003-09-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2447400

Other languages

English (en)

Inventor

Peter B. Dirks

Sheila K. Singh

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Hospital for Sick Children HSC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-12

Filing date

2003-10-30

Publication date

2005-03-12

2003-10-30 Application filed by Hospital for Sick Children HSC filed Critical Hospital for Sick Children HSC

2005-03-12 Publication of CA2447400A1 publication Critical patent/CA2447400A1/fr

Status Abandoned legal-status Critical Current

Links

210000000130 stem cell Anatomy 0.000 title claims abstract description 153
208000003174 Brain Neoplasms Diseases 0.000 title claims abstract description 131
206010028980 Neoplasm Diseases 0.000 claims abstract description 182
101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims abstract description 91
102100040120 Prominin-1 Human genes 0.000 claims abstract description 91
239000002458 cell surface marker Substances 0.000 claims abstract description 14
238000012216 screening Methods 0.000 claims abstract description 9
210000004027 cell Anatomy 0.000 claims description 207
208000000172 Medulloblastoma Diseases 0.000 claims description 76
210000004881 tumor cell Anatomy 0.000 claims description 46
238000000034 method Methods 0.000 claims description 45
206010003571 Astrocytoma Diseases 0.000 claims description 43
230000004069 differentiation Effects 0.000 claims description 33
102000008730 Nestin Human genes 0.000 claims description 24
108010088225 Nestin Proteins 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 24
210000005055 nestin Anatomy 0.000 claims description 24
230000035755 proliferation Effects 0.000 claims description 18
230000000694 effects Effects 0.000 claims description 14
210000004556 brain Anatomy 0.000 claims description 13
206010018338 Glioma Diseases 0.000 claims description 11
101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 11
241001465754 Metazoa Species 0.000 claims description 11
102100038081 Signal transducer CD24 Human genes 0.000 claims description 11
230000002062 proliferating effect Effects 0.000 claims description 11
201000004066 Ganglioglioma Diseases 0.000 claims description 10
238000011579 SCID mouse model Methods 0.000 claims description 9
238000004393 prognosis Methods 0.000 claims description 9
208000014534 anaplastic ependymoma Diseases 0.000 claims description 8
208000005017 glioblastoma Diseases 0.000 claims description 8
206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims description 7
206010026659 Malignant oligodendroglioma Diseases 0.000 claims description 7
206010002224 anaplastic astrocytoma Diseases 0.000 claims description 7
208000027671 high grade ependymoma Diseases 0.000 claims description 7
238000000338 in vitro Methods 0.000 claims description 7
208000030883 malignant astrocytoma Diseases 0.000 claims description 7
210000004958 brain cell Anatomy 0.000 claims description 6
238000001727 in vivo Methods 0.000 claims description 6
238000001574 biopsy Methods 0.000 claims description 2
210000005260 human cell Anatomy 0.000 claims description 2
206010061598 Immunodeficiency Diseases 0.000 claims 2
238000012360 testing method Methods 0.000 abstract description 3
230000001093 anti-cancer Effects 0.000 abstract 1
210000001178 neural stem cell Anatomy 0.000 description 42
230000014509 gene expression Effects 0.000 description 25
238000003556 assay Methods 0.000 description 20
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 17
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 17
230000001537 neural effect Effects 0.000 description 17
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 15
201000007286 Pilocytic astrocytoma Diseases 0.000 description 15
238000004458 analytical method Methods 0.000 description 14
102000004243 Tubulin Human genes 0.000 description 12
108090000704 Tubulin Proteins 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 11
210000001130 astrocyte Anatomy 0.000 description 11
208000036815 beta tubulin Diseases 0.000 description 11
239000003550 marker Substances 0.000 description 10
210000002569 neuron Anatomy 0.000 description 10
208000011581 secondary neoplasm Diseases 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 9
201000011510 cancer Diseases 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
238000000684 flow cytometry Methods 0.000 description 9
239000000523 sample Substances 0.000 description 8
230000003595 spectral effect Effects 0.000 description 8
101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 7
102100033237 Pro-epidermal growth factor Human genes 0.000 description 7
102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
238000002955 isolation Methods 0.000 description 7
238000007747 plating Methods 0.000 description 7
239000012679 serum free medium Substances 0.000 description 7
238000010186 staining Methods 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
239000002771 cell marker Substances 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
238000003365 immunocytochemistry Methods 0.000 description 6
210000004248 oligodendroglia Anatomy 0.000 description 6
230000001575 pathological effect Effects 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
230000001464 adherent effect Effects 0.000 description 5
239000011324 bead Substances 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
238000001516 cell proliferation assay Methods 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
230000001605 fetal effect Effects 0.000 description 5
230000012447 hatching Effects 0.000 description 5
238000012744 immunostaining Methods 0.000 description 5
230000031864 metaphase Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000010494 dissociation reaction Methods 0.000 description 4
230000005593 dissociations Effects 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
238000003364 immunohistochemistry Methods 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
238000011002 quantification Methods 0.000 description 4
230000009466 transformation Effects 0.000 description 4
231100000588 tumorigenic Toxicity 0.000 description 4
230000000381 tumorigenic effect Effects 0.000 description 4
208000037068 Abnormal Karyotype Diseases 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 3
230000004075 alteration Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
231100000504 carcinogenesis Toxicity 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000011521 glass Substances 0.000 description 3
210000003958 hematopoietic stem cell Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
238000007798 limiting dilution analysis Methods 0.000 description 3
239000002243 precursor Substances 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000013207 serial dilution Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
210000001988 somatic stem cell Anatomy 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
206010014967 Ependymoma Diseases 0.000 description 2
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000012411 Intermediate Filament Proteins Human genes 0.000 description 2
108010061998 Intermediate Filament Proteins Proteins 0.000 description 2
108090000192 Methionyl aminopeptidases Proteins 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
102000008763 Neurofilament Proteins Human genes 0.000 description 2
108010088373 Neurofilament Proteins Proteins 0.000 description 2
201000010133 Oligodendroglioma Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000007398 colorimetric assay Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000002559 cytogenic effect Effects 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000007877 drug screening Methods 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000002509 fluorescent in situ hybridization Methods 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
238000007885 magnetic separation Methods 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
210000003061 neural cell Anatomy 0.000 description 2
210000005044 neurofilament Anatomy 0.000 description 2
230000007514 neuronal growth Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
108010055896 polyornithine Proteins 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
210000004129 prosencephalon Anatomy 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 1
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
241000283707 Capra Species 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
206010014968 Ependymoma malignant Diseases 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
108010064983 Ovomucin Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
208000037323 Rare tumor Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000003140 astrocytic effect Effects 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
238000002737 cell proliferation kit Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
210000002230 centromere Anatomy 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
201000005793 childhood medulloblastoma Diseases 0.000 description 1
230000003021 clonogenic effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
YQDHCCVUYCIGSW-LBPRGKRZSA-N ethyl (2s)-2-benzamido-5-(diaminomethylideneamino)pentanoate Chemical group NC(=N)NCCC[C@@H](C(=O)OCC)NC(=O)C1=CC=CC=C1 YQDHCCVUYCIGSW-LBPRGKRZSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
-1 for astrocytes) Proteins 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000012760 immunocytochemical staining Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000003963 intermediate filament Anatomy 0.000 description 1
230000016507 interphase Effects 0.000 description 1
210000000661 isochromosome Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
208000030173 low grade glioma Diseases 0.000 description 1
238000007898 magnetic cell sorting Methods 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000010208 microarray analysis Methods 0.000 description 1
239000011325 microbead Substances 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000002894 multi-fate stem cell Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
210000000441 neoplastic stem cell Anatomy 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
210000005155 neural progenitor cell Anatomy 0.000 description 1
208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
231100001221 nontumorigenic Toxicity 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
206010073131 oligoastrocytoma Diseases 0.000 description 1
230000006548 oncogenic transformation Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
201000004346 pediatric infratentorial ependymoma Diseases 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000002629 repopulating effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000001913 submandibular gland Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000001587 telencephalon Anatomy 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
238000001665 trituration Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Oncology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Developmental Biology & Embryology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA 2447400 2003-09-12 2003-10-30 Cellules souches caracteristiques de tumeurs cerebrales Abandoned CA2447400A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50239503P	2003-09-12	2003-09-12
US60/502,395		2003-09-12

Publications (1)

Publication Number	Publication Date
CA2447400A1 true CA2447400A1 (fr)	2005-03-12

Family

ID=34273088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2447400 Abandoned CA2447400A1 (fr)	2003-09-12	2003-10-30	Cellules souches caracteristiques de tumeurs cerebrales

Country Status (1)

Country	Link
CA (1)	CA2447400A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006030473A1 (fr) *	2004-09-15	2006-03-23	Apogenix Gmbh	Procede de purification et d'amplification de cellules souches tumorales
WO2006051405A3 (fr) *	2004-11-12	2006-10-19	Univ Cambridge Tech	Procedes et moyens lies aux cellules souches cancereuses
WO2008033393A3 (fr) *	2006-09-11	2008-11-27	Univ Florida	Isolement, expansion et utilisation de cellules souches tumorales
WO2009043159A1 (fr) *	2007-10-01	2009-04-09	The Hospital For Sick Children	Cellules souches tumorales neurales et leurs procédés d'utilisation
WO2010028820A3 (fr) *	2008-09-10	2010-06-17	Life & Brain Gmbh	Cellules tumorales de zone périphérique, procédés de préparation et d'utilisation de celle-ci
EP3330373A1 (fr) *	2012-08-03	2018-06-06	Ulrich Pachmann	Procédé de culture d'une sous-population de cellules tumorales épithéliales circulantes provenant d'un fluide corporel
US10018630B2 (en)	2011-09-07	2018-07-10	Chugai Seiyaku Kabushiki Kaisha	Cancer stem cell isolation
WO2018165528A1 (fr) *	2017-03-09	2018-09-13	Thomas Jefferson University	Procédés et compositions de traitement de cancers à l'aide d'acides nucléiques antisens
WO2018224761A1 (fr) *	2017-06-08	2018-12-13	Carcidiag Biotechnologies	Methode d'isolement et de detection de cellules souches cancereuses
US10543226B2 (en)	2015-04-10	2020-01-28	Thomas Jefferson University	Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
US10934351B2 (en)	2011-10-28	2021-03-02	Chugai Seiyaku Kabushiki Kaisha	Cancer stem cell-specific molecule
US11124773B2 (en)	2010-10-06	2021-09-21	Chugai Seiyaku Kabushiki Kaisha	Cancer stem cell population and method for production thereof
CN113528447A (zh) *	2021-06-10	2021-10-22	广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院）	一种微流控芯片及其在肿瘤干细胞分选、扩增、回收中的应用
US11536713B2 (en)	2009-12-25	2022-12-27	Chugai Seiyaku Kabushiki Kaisha	Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
CN115521916A (zh) *	2022-10-11	2022-12-27	中国人民解放军中部战区总医院	人脑胶质母细胞瘤原代肿瘤干细胞的培养鉴定方法

2003
- 2003-10-30 CA CA 2447400 patent/CA2447400A1/fr not_active Abandoned

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006030473A1 (fr) *	2004-09-15	2006-03-23	Apogenix Gmbh	Procede de purification et d'amplification de cellules souches tumorales
EP2006374A3 (fr) *	2004-09-15	2009-05-27	Apogenix GmbH	Procédé pour la purification et l'amplification de cellules souches tumorales
WO2006051405A3 (fr) *	2004-11-12	2006-10-19	Univ Cambridge Tech	Procedes et moyens lies aux cellules souches cancereuses
US10538742B2 (en)	2004-11-12	2020-01-21	Cambridge Enterprise Limited	Methods and means related to cancer stem cells
WO2008033393A3 (fr) *	2006-09-11	2008-11-27	Univ Florida	Isolement, expansion et utilisation de cellules souches tumorales
WO2009043159A1 (fr) *	2007-10-01	2009-04-09	The Hospital For Sick Children	Cellules souches tumorales neurales et leurs procédés d'utilisation
GB2465940A (en) *	2007-10-01	2010-06-09	Hospital For Sick Children	Neural tumor stem cells and methods of use thereof
AU2009291203B2 (en) *	2008-09-10	2015-01-22	Life & Brain Gmbh	Peripheral zone tumor cells, methods for their preparation and use
US9103819B2 (en)	2008-09-10	2015-08-11	Rheinische Friedrich-Wilhelms-Universität Bonn	Peripheral zone tumor cells, methods for their preparation and use
WO2010028820A3 (fr) *	2008-09-10	2010-06-17	Life & Brain Gmbh	Cellules tumorales de zone périphérique, procédés de préparation et d'utilisation de celle-ci
US11536713B2 (en)	2009-12-25	2022-12-27	Chugai Seiyaku Kabushiki Kaisha	Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
US11965180B2 (en)	2010-10-06	2024-04-23	Chugai Seiyaku Kabushiki Kaisha	Cancer stem cell population and method for production thereof
US11124773B2 (en)	2010-10-06	2021-09-21	Chugai Seiyaku Kabushiki Kaisha	Cancer stem cell population and method for production thereof
US10018630B2 (en)	2011-09-07	2018-07-10	Chugai Seiyaku Kabushiki Kaisha	Cancer stem cell isolation
US11858987B2 (en)	2011-10-28	2024-01-02	Chugai Seiyaku Kabushiki Kaisha	Cancer stem cell-specific molecule
US10934351B2 (en)	2011-10-28	2021-03-02	Chugai Seiyaku Kabushiki Kaisha	Cancer stem cell-specific molecule
EP3330373A1 (fr) *	2012-08-03	2018-06-06	Ulrich Pachmann	Procédé de culture d'une sous-population de cellules tumorales épithéliales circulantes provenant d'un fluide corporel
US12064446B2 (en)	2015-04-10	2024-08-20	Thomas Jefferson University	Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
US10543226B2 (en)	2015-04-10	2020-01-28	Thomas Jefferson University	Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
US11077133B2 (en)	2015-04-10	2021-08-03	Thomas Jefferson University	Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
US10357509B2 (en)	2017-03-09	2019-07-23	Thomas Jefferson University	Methods and compositions for treating cancers using antisense
US11801259B2 (en)	2017-03-09	2023-10-31	Thomas Jefferson University	Methods and compositions for treating cancers using antisense
US10772904B2 (en)	2017-03-09	2020-09-15	Thomas Jefferson University	Methods and compositions for treating cancers using antisense
WO2018165528A1 (fr) *	2017-03-09	2018-09-13	Thomas Jefferson University	Procédés et compositions de traitement de cancers à l'aide d'acides nucléiques antisens
IL268872B2 (en) *	2017-03-09	2025-04-01	Univ Jefferson	Methods and compositions for treating cancer using antisense
WO2018224761A1 (fr) *	2017-06-08	2018-12-13	Carcidiag Biotechnologies	Methode d'isolement et de detection de cellules souches cancereuses
US12455288B2 (en)	2017-06-08	2025-10-28	Sylvain Gnaho	Method of isolating and detecting cancer stem cells
CN113528447A (zh) *	2021-06-10	2021-10-22	广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院）	一种微流控芯片及其在肿瘤干细胞分选、扩增、回收中的应用
CN115521916A (zh) *	2022-10-11	2022-12-27	中国人民解放军中部战区总医院	人脑胶质母细胞瘤原代肿瘤干细胞的培养鉴定方法

Legal Events

Date	Code	Title	Description
2006-02-02	FZDE	Dead

Publication	Publication Date	Title
Singh et al.	2003	Identification of a cancer stem cell in human brain tumors
US7153686B2 (en)	2006-12-26	Compositions of enriched central nervous system stem cell and progenitor cell populations
Panchision et al.	2007	Optimized flow cytometric analysis of central nervous system tissue reveals novel functional relationships among cells expressing CD133, CD15, and CD24
Dietrich et al.	2002	Characterization of A2B5+ glial precursor cells from cryopreserved human fetal brain progenitor cells
US7795021B2 (en)	2010-09-14	Lineage restricted glial precursors from the central nervous system
CA2447400A1 (fr)	2005-03-12	Cellules souches caracteristiques de tumeurs cerebrales
JP2010252808A (ja)	2010-11-11	富化された中枢神経系の幹細胞および始原細胞の集団、ならびにこのような集団を同定、単離、および富化するための方法
JP2007503815A (ja)	2007-03-01	富化された膵臓幹細胞および前駆細胞集団、ならびにこれらの集団の同定、単離および富化方法
Kennedy et al.	1987	Antigenic expression by cells derived from human gliomas does not correlate with morphological classification
TW201319252A (zh)	2013-05-16	體幹細胞
JP2006511206A (ja)	2006-04-06	富化された中枢神経系幹細胞集団および前駆体細胞集団、ならびにこれらの集団を同定し、単離し、そして富化する方法
Tohda et al.	1993	Relationship between c‐kit expression and proliferation in acute myeloblastic leukemia cell lines
Yu et al.	2004	Isolation and characterization of the CD133+ precursors from the ventricular zone of human fetal brain by magnetic affinity cell sorting
US6890724B2 (en)	2005-05-10	Methods and compositions for neural progenitor cells
US7105150B2 (en)	2006-09-12	In vivo screening methods using enriched neural stem cells
US7037719B1 (en)	2006-05-02	Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US7217565B2 (en)	2007-05-15	Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US8119774B2 (en)	2012-02-21	Cell marker for hepatic and pancreatic stem cells and progenitor cells
Hayward et al.	1992	Patterns of growth and differentiation in the colon carcinoma cell line LIM 1863
CN101463342A (zh)	2009-06-24	人肺腺癌干细胞的分离鉴定方法
US20100086998A1 (en)	2010-04-08	Enriched Central Nervous System Stem Cell and Progenitor Cell Populations, and Methods For Identifying, Isolating and Enriching For Such Populations
Gogusev et al.	2020	Establishment and Characterization of a Stromal Cell Line Derived from a Patient with Thoracic Endometriosis
US20100323385A1 (en)	2010-12-23	Nitrogen independence identifies a highly malignant population of tumor stem cells
CN119410584A (zh)	2025-02-11	用于产生视网膜色素上皮细胞的方法和组合物
PANCHISION et al.	2007	TECHNOLOGY DEVELOPMENT